Search Results
Search for other papers by Maria Chiara Zatelli in
Google Scholar
PubMed
Search for other papers by Daniela Piccin in
Google Scholar
PubMed
Search for other papers by Cristina Vignali in
Google Scholar
PubMed
Search for other papers by Federico Tagliati in
Google Scholar
PubMed
Search for other papers by Maria Rosaria Ambrosio in
Google Scholar
PubMed
Search for other papers by Marta Bondanelli in
Google Scholar
PubMed
Search for other papers by Vincenzo Cimino in
Google Scholar
PubMed
Search for other papers by Antonio Bianchi in
Google Scholar
PubMed
Search for other papers by Herbert A Schmid in
Google Scholar
PubMed
Search for other papers by Massimo Scanarini in
Google Scholar
PubMed
Search for other papers by Alfredo Pontecorvi in
Google Scholar
PubMed
Search for other papers by Laura De Marinis in
Google Scholar
PubMed
Search for other papers by Giulio Maira in
Google Scholar
PubMed
Search for other papers by Ettore C degli Uberti in
Google Scholar
PubMed
vascularization. Previous evidence has shown that somatostatin (SRIF) and its analogs might exert antiproliferative effects on pituitary adenomas, by interacting with one or more of its five transmembrane G-protein-coupled receptors (SSTR1–5; Zatelli et
Search for other papers by V Craig Jordan in
Google Scholar
PubMed
provide their raw data for inclusion in the overview analysis that would be updated every 5 years. The publication in 1998 ( Early Breast Cancer Trialists’ Collaborative Group 1998 ) not only focused specifically on the worth of tamoxifen as a targeted
Search for other papers by Katrin-Janine Heiliger in
Google Scholar
PubMed
Search for other papers by Julia Hess in
Google Scholar
PubMed
Search for other papers by Donata Vitagliano in
Google Scholar
PubMed
Search for other papers by Paolo Salerno in
Google Scholar
PubMed
Search for other papers by Herbert Braselmann in
Google Scholar
PubMed
Search for other papers by Giuliana Salvatore in
Google Scholar
PubMed
Search for other papers by Clara Ugolini in
Google Scholar
PubMed
Search for other papers by Isolde Summerer in
Google Scholar
PubMed
Search for other papers by Tatjana Bogdanova in
Google Scholar
PubMed
Search for other papers by Kristian Unger in
Google Scholar
PubMed
Search for other papers by Gerry Thomas in
Google Scholar
PubMed
Search for other papers by Massimo Santoro in
Google Scholar
PubMed
Search for other papers by Horst Zitzelsberger in
Google Scholar
PubMed
-Trk-T1 mice were euthanised and thyroids were immediately fixed in buffered formalin for 4 h at room temperature. Tissues underwent automated processing and paraffin embedding; 5 μm sections were cut and haematoxylin and eosin stained (H&E) for
Department of Oncology, Medical University of Warsaw, Warsaw, Poland
Search for other papers by Piotr T Wysocki in
Google Scholar
PubMed
Search for other papers by Karol Czubak in
Google Scholar
PubMed
Search for other papers by Anna A Marusiak in
Google Scholar
PubMed
Search for other papers by Monika Kolanowska in
Google Scholar
PubMed
Department of Immunology, Medical University of Warsaw, Warsaw, Poland
Search for other papers by Dominika Nowis in
Google Scholar
PubMed
(47 cases of conventional variant of PTC (cPTC), 9 follicular variant PTCs (fvPTC), 5 FTCs, 1 FTC + fvPTC, 3 HTCs, 2 DTCs with incomplete histological data). All patients provided written informed consent. Histological material was evaluated by
Université de Lyon, Inserm, Centre Léon Bérard, Laboratoire de Toxicologie, Laboratoire de Ciblage Thérapeutique en Cancérologie, Centre René Huguenin, Inserm, University of Illinois at Chicago Cancer Center, Lyon1, ISPB, Lyon F-69008, France
Université de Lyon, Inserm, Centre Léon Bérard, Laboratoire de Toxicologie, Laboratoire de Ciblage Thérapeutique en Cancérologie, Centre René Huguenin, Inserm, University of Illinois at Chicago Cancer Center, Lyon1, ISPB, Lyon F-69008, France
Search for other papers by Mylène Honorat in
Google Scholar
PubMed
Université de Lyon, Inserm, Centre Léon Bérard, Laboratoire de Toxicologie, Laboratoire de Ciblage Thérapeutique en Cancérologie, Centre René Huguenin, Inserm, University of Illinois at Chicago Cancer Center, Lyon1, ISPB, Lyon F-69008, France
Université de Lyon, Inserm, Centre Léon Bérard, Laboratoire de Toxicologie, Laboratoire de Ciblage Thérapeutique en Cancérologie, Centre René Huguenin, Inserm, University of Illinois at Chicago Cancer Center, Lyon1, ISPB, Lyon F-69008, France
Search for other papers by Aurelia Mesnier in
Google Scholar
PubMed
Université de Lyon, Inserm, Centre Léon Bérard, Laboratoire de Toxicologie, Laboratoire de Ciblage Thérapeutique en Cancérologie, Centre René Huguenin, Inserm, University of Illinois at Chicago Cancer Center, Lyon1, ISPB, Lyon F-69008, France
Université de Lyon, Inserm, Centre Léon Bérard, Laboratoire de Toxicologie, Laboratoire de Ciblage Thérapeutique en Cancérologie, Centre René Huguenin, Inserm, University of Illinois at Chicago Cancer Center, Lyon1, ISPB, Lyon F-69008, France
Search for other papers by Julie Vendrell in
Google Scholar
PubMed
Université de Lyon, Inserm, Centre Léon Bérard, Laboratoire de Toxicologie, Laboratoire de Ciblage Thérapeutique en Cancérologie, Centre René Huguenin, Inserm, University of Illinois at Chicago Cancer Center, Lyon1, ISPB, Lyon F-69008, France
Université de Lyon, Inserm, Centre Léon Bérard, Laboratoire de Toxicologie, Laboratoire de Ciblage Thérapeutique en Cancérologie, Centre René Huguenin, Inserm, University of Illinois at Chicago Cancer Center, Lyon1, ISPB, Lyon F-69008, France
Search for other papers by Jérôme Guitton in
Google Scholar
PubMed
Université de Lyon, Inserm, Centre Léon Bérard, Laboratoire de Toxicologie, Laboratoire de Ciblage Thérapeutique en Cancérologie, Centre René Huguenin, Inserm, University of Illinois at Chicago Cancer Center, Lyon1, ISPB, Lyon F-69008, France
Search for other papers by Ivan Bieche in
Google Scholar
PubMed
Université de Lyon, Inserm, Centre Léon Bérard, Laboratoire de Toxicologie, Laboratoire de Ciblage Thérapeutique en Cancérologie, Centre René Huguenin, Inserm, University of Illinois at Chicago Cancer Center, Lyon1, ISPB, Lyon F-69008, France
Search for other papers by Rosette Lidereau in
Google Scholar
PubMed
Search for other papers by Gary D Kruh in
Google Scholar
PubMed
Université de Lyon, Inserm, Centre Léon Bérard, Laboratoire de Toxicologie, Laboratoire de Ciblage Thérapeutique en Cancérologie, Centre René Huguenin, Inserm, University of Illinois at Chicago Cancer Center, Lyon1, ISPB, Lyon F-69008, France
Université de Lyon, Inserm, Centre Léon Bérard, Laboratoire de Toxicologie, Laboratoire de Ciblage Thérapeutique en Cancérologie, Centre René Huguenin, Inserm, University of Illinois at Chicago Cancer Center, Lyon1, ISPB, Lyon F-69008, France
Search for other papers by Charles Dumontet in
Google Scholar
PubMed
Université de Lyon, Inserm, Centre Léon Bérard, Laboratoire de Toxicologie, Laboratoire de Ciblage Thérapeutique en Cancérologie, Centre René Huguenin, Inserm, University of Illinois at Chicago Cancer Center, Lyon1, ISPB, Lyon F-69008, France
Université de Lyon, Inserm, Centre Léon Bérard, Laboratoire de Toxicologie, Laboratoire de Ciblage Thérapeutique en Cancérologie, Centre René Huguenin, Inserm, University of Illinois at Chicago Cancer Center, Lyon1, ISPB, Lyon F-69008, France
Search for other papers by Pascale Cohen in
Google Scholar
PubMed
Université de Lyon, Inserm, Centre Léon Bérard, Laboratoire de Toxicologie, Laboratoire de Ciblage Thérapeutique en Cancérologie, Centre René Huguenin, Inserm, University of Illinois at Chicago Cancer Center, Lyon1, ISPB, Lyon F-69008, France
Université de Lyon, Inserm, Centre Léon Bérard, Laboratoire de Toxicologie, Laboratoire de Ciblage Thérapeutique en Cancérologie, Centre René Huguenin, Inserm, University of Illinois at Chicago Cancer Center, Lyon1, ISPB, Lyon F-69008, France
Université de Lyon, Inserm, Centre Léon Bérard, Laboratoire de Toxicologie, Laboratoire de Ciblage Thérapeutique en Cancérologie, Centre René Huguenin, Inserm, University of Illinois at Chicago Cancer Center, Lyon1, ISPB, Lyon F-69008, France
Search for other papers by Lea Payen in
Google Scholar
PubMed
with ER-negative and ER-positive hormone-refractory breast cancers. Standard agents include cyclophosphamide, methotrexate, vinca alkaloids anthracyclines, taxanes, and 5-fluorouracil (5-FU), with the latter agent recently assuming a larger role as a
Search for other papers by V Craig Jordan in
Google Scholar
PubMed
Walpole again 5 years later in 1972, but this time he was the examiner of my PhD thesis entitled ‘A study of the structure function relationship of substituted triphenylethylenes and triphenylethanes’. Figure 3 The principal players in the discovery of ICI
Search for other papers by Kreepa G Kooblall in
Google Scholar
PubMed
Search for other papers by Victoria J Stokes in
Google Scholar
PubMed
Search for other papers by Omair A Shariq in
Google Scholar
PubMed
Search for other papers by Katherine A English in
Google Scholar
PubMed
Search for other papers by Mark Stevenson in
Google Scholar
PubMed
Search for other papers by John Broxholme in
Google Scholar
PubMed
Search for other papers by Benjamin Wright in
Google Scholar
PubMed
Search for other papers by Helen E Lockstone in
Google Scholar
PubMed
Search for other papers by David Buck in
Google Scholar
PubMed
Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed
Search for other papers by Christopher J Yates in
Google Scholar
PubMed
Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust, Oxford, UK
Search for other papers by Rajesh V Thakker in
Google Scholar
PubMed
Search for other papers by Kate E Lines in
Google Scholar
PubMed
screening for tumours, from as young as 5 years of age. Current clinical guidelines recommend annual surveillance for tumours by biochemical analyses (e.g. calcium, fasting glucose and hormones such as insulin, gastrin and prolactin) and radiological
Search for other papers by Manisha Taya in
Google Scholar
PubMed
Search for other papers by Maria de la Luz Garcia-Hernandez in
Google Scholar
PubMed
Search for other papers by Javier Rangel-Moreno in
Google Scholar
PubMed
Search for other papers by Briaunna Minor in
Google Scholar
PubMed
Search for other papers by Erin Gibbons in
Google Scholar
PubMed
Search for other papers by Stephen R Hammes in
Google Scholar
PubMed
Subjects Review Board. Tissues were paraffin embedded and processed into 5 μm sections. Sections were deparaffinized and rehydrated for immunofluorescence and hematoxylin and eosin (H&E) staining. Cell cultures and reagents Human TSC2 -null 621
Search for other papers by Xiaoli Liu in
Google Scholar
PubMed
Search for other papers by Chunhai Zhang in
Google Scholar
PubMed
Search for other papers by Xiaomiao Wang in
Google Scholar
PubMed
Search for other papers by Can Cui in
Google Scholar
PubMed
Search for other papers by Hanwen Cui in
Google Scholar
PubMed
Search for other papers by Baishu Zhu in
Google Scholar
PubMed
Search for other papers by Anqi Chen in
Google Scholar
PubMed
Search for other papers by Lu Zhang in
Google Scholar
PubMed
Search for other papers by Jingwei Xin in
Google Scholar
PubMed
Search for other papers by Qingfeng Fu in
Google Scholar
PubMed
Division of Surgery, Istituto Auxologico Italiano, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
Search for other papers by Gianlorenzo Dionigi in
Google Scholar
PubMed
Search for other papers by Hui Sun in
Google Scholar
PubMed
He S Yang Q Guo W Lai Y Du H Peng X 2019 Copy number gain of ZEB1 mediates a double-negative feedback loop with miR-33a-5p that regulates EMT and bone metastasis of prostate cancer dependent on TGF-beta signaling . Theranostics 9 6063
Department of Thyroid Surgery, Key Discipline Laboratory of Clinical Medicine Henan, Department of Endocrinology, Division of Radiobiology, Division of Endocrinology and Metabolism, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, People's Republic of China
Search for other papers by De-tao Yin in
Google Scholar
PubMed
Search for other papers by Wenxun Wu in
Google Scholar
PubMed
Department of Thyroid Surgery, Key Discipline Laboratory of Clinical Medicine Henan, Department of Endocrinology, Division of Radiobiology, Division of Endocrinology and Metabolism, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, People's Republic of China
Search for other papers by Mingchuang Li in
Google Scholar
PubMed
Search for other papers by Qi-en Wang in
Google Scholar
PubMed
Department of Thyroid Surgery, Key Discipline Laboratory of Clinical Medicine Henan, Department of Endocrinology, Division of Radiobiology, Division of Endocrinology and Metabolism, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, People's Republic of China
Search for other papers by Hongqiang Li in
Google Scholar
PubMed
Department of Thyroid Surgery, Key Discipline Laboratory of Clinical Medicine Henan, Department of Endocrinology, Division of Radiobiology, Division of Endocrinology and Metabolism, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, People's Republic of China
Search for other papers by Yongfei Wang in
Google Scholar
PubMed
Department of Thyroid Surgery, Key Discipline Laboratory of Clinical Medicine Henan, Department of Endocrinology, Division of Radiobiology, Division of Endocrinology and Metabolism, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, People's Republic of China
Search for other papers by Yifeng Tang in
Google Scholar
PubMed
Search for other papers by Mingzhao Xing in
Google Scholar
PubMed
Q Shen RL Gao JX He G 2010a Homozygous deletion but not mutation of exons 5 and 8 of the fragile histidine triad (FHIT) gene is associated with features of differentiated thyroid carcinoma . Annals of Clinical Laboratory Science 40 267